Our testing shows that TA is a very broad-spectrum antiviral drug, effective against Influenza A and B, and likely part of the first line of defense against the recurring pandemic respiratory viruses. It also appears to be effective against cold viruses. TA could be developed as a monotherapy, but combinations with existing therapies would also make therapeutic as well as strategic sense.
Extensive method and composition patent filings covering synthetic analogs, derivatives, and mimetics, and a new means of administration not currently on the market for TA, provide protectability.
We believe our current data allows the beginning of Phase 2/3 clinical studies now, using TA alone or in combinations. Expedited handling by the FDA should be available.